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Candida albicans is an important human pathogen and a major concern in intensive
care units around the world. C. albicans infections are associated with a high mortality
despite the use of antifungal treatments. One of the causes of therapeutic failures
is the acquisition of antifungal resistance by mutations in the C. albicans genome.
Fluconazole (FLC) is one of the most widely used antifungal and mechanisms of FLC
resistance occurring by mutations have been extensively investigated. However, some
clinical isolates are known to be able to survive at high FLC concentrations without
acquiring resistance mutations, a phenotype known as tolerance. Mechanisms behind
FLC tolerance are not well studied, mainly due to the lack of a proper way to identify and
quantify tolerance in clinical isolates. We proposed here culture conditions to investigate
FLC tolerance as well as an easy and efficient method to identity and quantify tolerance
to FLC. The screening of C. albicans strain collections revealed that FLC tolerance
is pH- and strain-dependent, suggesting the involvement of multiple mechanisms.
Here, we addressed the identification of FLC tolerance mediators in C. albicans by
an overexpression strategy focusing on 572 C. albicans genes. This strategy led to
the identification of two transcription factors, CRZ1 and GZF3. CRZ1 is a C2H2-type
transcription factor that is part of the calcineurin-dependent pathway in C. albicans,
while GZF3 is a GATA-type transcription factor of unknown function in C. albicans.
Overexpression of each gene resulted in an increase of FLC tolerance, however, only
the deletion of CRZ1 in clinical FLC-tolerant strains consistently decreased their FLC
tolerance. Transcription profiling of clinical isolates with variable levels of FLC tolerance
confirmed a calcineurin-dependent signature in these isolates when exposed to FLC.
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INTRODUCTION
Candida species are major fungal pathogens which can cause
life-threatening systemic infection known as invasive candidiasis.
Candida infection are linked to a high mortality rate despite
treatments with antifungals. Therapeutic failures might be
partially explained by acquisition of resistance upon treatment
(Pfaller and Diekema, 2010). Azoles, and particularly fluconazole
(FLC), are still widely used in the management of fungal infection
including C. albicans infections (Berman and Krysan, 2020).
Resistance mechanisms to FLC have been extensively studied
(Morschhäuser, 2016). However, despite an extensive knowledge
of these mechanisms, the acquisition of resistance does not
explain all therapeutic failures. Indeed, it has been observed that
some isolates identified as susceptible to FLC in vitro cannot be
treated efficiently in the patient. It is known that some clinical
isolates of C. albicans tolerate the presence of FLC more than
others. These are characterized by an increased growth, known
as residual growth, at drug concentrations above their minimum
inhibitory concentration (MIC). This residual growth, which is
a characteristic of drug tolerance, is in general not coupled to
an increased MIC (unlike resistance) and is thought to favor the
acquisition of resistance mechanisms due to extended survival
of some C. albicans isolates upon treatment. Tolerant isolates
may also to be a source of reinfection upon arrest of antifungal
treatment (Delarze and Sanglard, 2015).
A few mechanisms have been linked to FLC tolerance
in C. albicans in the past, even if a clear definition of
tolerance was not yet available. It was demonstrated that
the immunosuppressive drug cyclosporine could convert the
fungistatic drug FLC into a strong fungicidal agent in vitro, thus
reflecting a loss of tolerance (Sanglard et al., 2003). Cyclosporine
A, associated with cyclophilin A (CYP), targets calcineurin,
which is a protein phosphatase activated by a calcium-dependent
pathway (Sanglard, 2003). Exposure of the calcineurin subunit A
(CNA/CMP1) deletion mutant to FLC results in a strong loss of
viability reflecting a loss of tolerance for the drug. In contrast,
the deletion of the CYP gene was viable in presence of FLC and
cyclosporine A. Calcineurin regulates drug tolerance only and not
resistance, since the presence or absence of its activity does not
affect drug susceptibility in drug susceptibility assays (Sanglard
et al., 2003). The calcineurin pathway leads to the activation
of a transcription factor (CRZ1), which itself was reported to
modify FLC tolerance (Onyewu et al., 2004; Karababa et al., 2006).
Calcineurin was also shown to be a client protein of the chaperone
heat shock protein 90 (Hsp90) (Cowen, 2008). Inhibition of
Hsp90 results in a loss of calcineurin activity and, therefore, in
a loss of FLC tolerance such as observed with the CNA deletion
mutant (Cowen, 2013). In another study (Luna-Tapia et al., 2015),
it was shown that the membrane trafficking through the late
endosome/pre-vacuolar compartment (PVC) had an impact on
C. albicans FLC tolerance. Deletion of VPS21, an endosomal Rab
family GTPase involved in PVC trafficking, resulted in enhanced
growth in the presence of FLC. This enhanced growth appeared
as trailing growth in standard susceptibility assays, thus pointing
to a potential role of Vps21 in azole tolerance. In addition, the
VPS21 mutant contained abnormally high levels of intracellular
Ca2+, thus potentially increasing the basal level of calcineurin
expression and/or activation (Luna-Tapia et al., 2015). It has
also been observed that Rta3, a putative lipid translocase, is
co-upregulated with multidrug transporters by the transcription
factor TAC1 in resistant C. albicans strains. While deletion of
RTA3 increases the susceptibility to FLC, overexpression of RTA3
results in an increase of tolerance characterized by a trailing
growth in the susceptible C. albicans strain SC5314 (Whaley
et al., 2016). Recently, it was reported that FEN1 and FEN12,
two C. albicans genes involved in sphingolipid biosynthesis,
may be involved in FLC tolerance. Indeed, deletion of FEN1
or FEN12 resulted in increased tolerance in the presence of
FLC. The increased survival of the mutants was linked to an
increased intracellular FLC concentration and a decreased level
in the plasma membrane of the toxic sterol 14-methylergosta-
8,24(28)-dien-3,6-diol responsible for the toxic effect of FLC in
C. albicans. These modifications in toxic sterol concentrations
were reflected by a high level of sphingolipids which improved
cell membrane strength (Gao et al., 2018). Another recently
published study highlighted a tolerance mechanism involving
the pH response via the Rim pathway. This pathway includes
Rim9, Rim21/Dfg16, Rim8, Rim20, and Rim13. Under neutral-
alkaline pH, this cascade leads to the cleavage of the C-terminal
inhibitory domain of the transcription factor Rim101 leading
to its activation. The culture medium’s pH was already known
to impact the level of tolerance in vitro (Marr et al., 1999)
and it has been observed that tolerance decreases under acidic
conditions, while it is not affected in neutral conditions (pH 6–
7). A phenotypic and transcriptomic analysis of the Rim pathway
showed that all Rim proteins were important for FLC tolerance
since their respective deletion mutants exhibited increased
FLC susceptibility (Garnaud et al., 2018). The transcriptomic
comparison between a RIM101 deletion mutant and a wild type
strain at alkaline and acidic pH led to the identification of
two Rim101 downstream targets, including HSP90 and IPT1.
HSP90 is already known to be involved in antifungal tolerance
on the opposite to IPT1, which encodes an enzyme involved
in the biosynthesis of the most abundant sphingolipid in the
plasma membrane [mannose-(inositol-P)2-ceramide] (Garnaud
et al., 2018). Interestingly, Ipt1 is part of the sphingolipid’s
biosynthesis pathway and is situated downstream of Fen1 and
Fen12, both of which were reported as FLC tolerance mediators
(see above). These data thus reinforce the idea that sphingolipids
homeostasis is of relevance for FLC tolerance in C. albicans.
In addition to these genotypic/phenotypic relationships, recent
studies highlighted that FLC tolerance can develop in clinical
strains from distinct subpopulations (Rosenberg et al., 2018).
Even if the above-listed mechanisms may lead to azole
tolerance, the exact molecular basis of tolerance is still not
completely understood. Moreover, most of these mechanisms
have not been proven to mediate tolerance in clinical isolates.
Tolerance may allow a better survival of C. albicans at high
drug concentrations. The strong selective pressure induced
by administered drugs and persistence resulting from residual
growth may favor the acquisition of resistance mechanisms and
may ultimately lead to treatment failure. Unraveling genetic and
epigenetic mechanisms underlying tolerance and the discovery
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of tolerance mediators are essential steps for the development of
potential inhibitors that, in combination with FLC, might offer
new strategies to fight against Candida infections.
In this study, we first adapted a standardized microdilution
method to measure tolerance in a subset of C. albicans clinical
isolates. We next addressed the identification of mediators of FLC
tolerance using a gene overexpression strategy in a laboratory
C. albicans strain. This strategy has been already effective in
the identification of genes associated with biofilm formation
and gut colonization (Znaidi et al., 2018). Starting with a
limited pool of C. albicans genes, we were able to identify
at least two transcription factors (CRZ1, GZF3) as mediators
of FLC tolerance. One of them, CRZ1, a transcription factor
under the control of the calcium-dependent calcineurin pathway,
was shown as critical in the maintenance of FLC tolerance of
several clinical strains. Consistent with this finding, we showed
by transcriptional analysis of clinical strains that the calcium-
dependent calcineurin pathway was stimulated by FLC exposure.
MATERIALS AND METHODS
Strains Used in This Study
The wild type (WT) strain SC5314 and the C. albicans clinical
isolates used in this study were selected for their known
susceptibility to FLC and belong to D. Sanglard’s lab collection
(Supplementary File S1). SSI strains were kindly provided by
M. C. Arendrup (Staten Serum Institute, Copenhagen, Denmark)
and M. E. Bougnoux (Institut Pasteur, Paris, France) provided the
CEC strain collection (Supplementary File S1). The collection
of 572 Tet-inducible overexpression barcoded and detectable
C. albicans strains used in this study was kindly provided by C.
d’Enfert (Supplementary File S2). Each strain of the collection
overexpresses a specific gene (or gene of interest, GOI) encoding
transcription factors, protein kinases, protein phosphatases,
proteins related to DNA replication, recombination and repair,
predicted cell surface proteins, or others, under the control
of tetracycline. The collection was constructed as described by
Chauvel et al. (2012). To test optimal overexpression culture
condition, the strain CEC3083 was used which overexpresses
the Gaussia princeps luciferase (gLUC). This strain was built in
parallel to the OE collection and also provided by C. d’Enfert
(Supplementary Table S1) (Chauvel et al., 2012). The clinical
C. albicans isolates used for the overexpression and deletion of
the candidate regulators of tolerance were part of D. Sanglard’s
laboratory collection (Supplementary Table S1). CRZ1 and
GZF3 deletion mutants as well as the double crz11/1, gzf31/1
mutants originating from the Homann’s transcription factor
deletion library are listed in Supplementary Table S1 (Homann
et al., 2009). Escherichia coli DH5α was used as a host for plasmid
construction and propagation.
Media and Growth Conditions
All fungal strains were stored in 20% glycerol at −80◦C and
routinely grown at 30◦C under constant shaking (220 rpm)
in complete Yeast Extract Peptone Dextrose (YEPD) medium
(1% Bacto peptone, Difco Laboratories, Basel, Switzerland),
0.5% Yeast extract (Difco) and 2% glucose (Fluka, Buchs,
Switzerland). When grown on solid YEPD plates (YEPDA), 2%
agar (Difco) was added and plates were incubated at 35◦C.
Bacteria were grown in Luria-Bertani (LB) broth or LB 2% agar
plates, supplemented with 100 µg/ml ampicillin (AppliChem,
Darmstadt, Germany) or 34 µg/ml chloramphenicol (Fluka)
when required and incubated at 37◦C.
For FLC susceptibility assays, strains were grown according
to the EUCAST or CLSI recommendations (Clinical and
Laboratory Standards Institute [CLSI], 2008; European
Committee on Antimicrobial Susceptibility Testing, 2017)
in RPMI1640 medium with phenol-red (Sigma-Aldrich, St.
Louis, United States), complemented with 0.2 or 2% glucose
(Fluka) and buffered with 0.33 M morpholinepropanesulfonic
acid (MOPS). The pH was adjusted to pH 7.5, pH 7, pH 6, and
pH 4.5, respectively, using NaOH or HCl. Stock solutions were
prepared as 2x concentrated RPMI as recommended by EUCAST
(European Committee on Antimicrobial Susceptibility Testing,
2017). RPMI was supplemented or not with FLC (Toronto
Research Chemicals, North York, Canada), doxycycline (Dox)
(Sigma-Aldrich) and iron (FeCl3) to compensate iron chelation
by Dox when necessary (Fiori and Van Dijck, 2012). For
luciferase assays, water-soluble coelenterazine (CTZ, NanoLight
Technology, Prolume Ltd. Pinetop, United States) was added
prior to measurement.
Primers and Plasmids
All primers used in this study are listed in Supplementary File
S3. Plasmids used in this study are listed in Supplementary File
S4. The insertion of each plasmid and gene deletion were verified
by PCR as stated in Supplementary File S3.
FLC Susceptibility and Tolerance Assays
All FLC susceptibility assays were performed according to the
Reference Method for Broth Dilution Antifungal Susceptibility
Testing of Yeasts (M27-A3) (Clinical and Laboratory Standards
Institute [CLSI], 2008) and the method for the determination of
broth dilution MICs of antifungal agents for yeasts (E.DEF 7.3.1)
(European Committee on Antimicrobial Susceptibility Testing,
2017) with slight modifications when necessary. Susceptibility
assays were performed in flat-bottom Costar R© 96-well plates
(Corning Inc, Corning, United States) and the fungal growth
was measured spectrophotometrically for both methods. The
minimal inhibitory concentration (MIC) was defined as the first
concentration of drug inhibiting at least 50% of fungal growth
as compared to a drug free control. Strains with a MIC below
4 µg/ml FLC were defined as susceptible as described by EUCAST
(European Committee on Antimicrobial Susceptibility Testing,
2017). Susceptibility assays were performed in RPMI at pH 7.5,
pH 7, pH 6 or pH 4. Tolerance assays were performed in the
same conditions but using one fixed only at FLC concentration
as specified in the corresponding experiment.
Briefly, individual colonies of each tested strain were grown
overnight in YEPD medium at 30◦C under constant shaking
(220 rpm). Cultures were centrifuged (5 min, 4600 rpm, 4◦C)
and washed twice with PBS (137 mM NaCl, 10 mM phosphate,
2.7 mM KCl, and pH 7.4). Cell concentration was estimated by
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spectrophotometry (OD540 nm) and cells resuspended at 5 × 105
cells/ml in distilled water. Then, 100 µl of this suspension were
transferred into the wells of flat-bottom 96-well plates containing
100 µl of 2x RPMI (0.2 or 2% glucose for CLSI and EUCAST
condition, respectively) complemented with 256–0 µg/ml FLC in
two-fold dilutions or fixed FLC concentrations, to obtain a final
cell concentration of 2.5 × 105 cells/ml and FLC concentrations
ranging from 128 to 0 µg/ml (8 µg/ml for tolerance assays) per
well. Plates were incubated at 35◦C without shaking for 24 h.
Cell growth in each well was measured by spectrophotometry
(OD570 nm) using a microplate reader (Multiskan Ascent,
Thermo Scientific) and compared to the drug-free control after
correction with a blank control. From these susceptibility curves,
both the MIC and the tolerance index (TI), corresponding to the
relative growth (% GC) at 8 µg/ml FLC divided by a factor 100
(TI = % GC/100) were extracted for strain comparisons. The TI
is used to determine the level of tolerance of the tested strains.
To assess the tolerance level of every single strain of the OE
collection and to remain in the same conditions compared to
the enrichment assay, tolerance assays of the collection were
performed at a final concentration of 32 µg/ml FLC instead
of 8 µg/ml.
Construction of Deletion Mutants and
Revertant Strains
The clinical isolates DSY2110, DSY4454, SSI 4622, and DSY4588
as well as the “WT,” the crz11/1 and the gzf31/1 strains from
the Homann’s collection (Homann et al., 2009) were used to
delete: (i) URA3, in order to transform the strains with the OE
system (Chauvel et al., 2012) and (ii) either CRZ1, GZF3 or
both to assess their role in FLC tolerance. All gene deletions
were performed by insertion of the PCR amplified 5′- and
3′- untranslated regions (UTR, 500 bp) into the SAT1-flipper
plasmid pSFS2A (Reuss et al., 2004). Details for the resulting
plasmids could be found in Supplementary File S4. URA3 was
deleted using the plasmid pSFSU1 (Supplementary File S4). Due
to technical issues with some clones, the second allele was deleted
by plating the heterozygous mutants on 5-fluoro-orotic acid (5-
FOA) to force deletion of the second allele as already described
(Wellington and Rustchenko, 2005). For deletion of CRZ1 and
GZF3, the plasmids pED19-2, pED20-7 and pET2-1 were used,
respectively (Supplementary File S4). The plasmid pET2-1 was
only used to delete the second GZF3 allele in DSY5217, resulting
in strain DSY5252.
All plasmids were transformed into their target strains
after digestion by KpnI and SacI to isolate the SAT1 flipper-
cassette. The transformants were plated and selected on YEPD
plates containing 200 µg/ml nourseothricin. The cassette was
flipped-out as described earlier (Reuss et al., 2004). To verify
gene deletions in selected isolates and the presence of the
wild type alleles, gene-specific primers were used in PCR
(Supplementary File S3).
To construct revertant strains in which CRZ1 and GZF3 were
reintroduced in the background of deletion mutants, the wild
type alleles from SC5314 and corresponding 5′- and 3′-UTR
(±500 bp) were reinserted by replacing the 5′-UTR of the deletion
plasmid by the CRZ1 and GZF3 amplified genes, resulting in
plasmids pLB1 and pET3, respectively (Supplementary File S4).
The wild type alleles were then reintroduced in addition to the
SAT1-flipper cassette into the homozygous mutants by KpnI and
SacI digestion of the plasmids.
Determination of Optimal Dox
Concentration for OE
To optimize the culture conditions for overexpression with the
OE collection, the ability of Dox to induce OE was evaluated
using the gLUC-OE strain CEC3083 (Supplementary Table S1).
Briefly, individual colonies were grown o/n in liquid YEPD
medium at 30◦C under constant shaking. The culture was then
centrifuged (5 min, 4600 rpm, 4◦C) and the cell pellet washed
twice with phosphate buffered saline (PBS). Cells were then
resuspended at 7.5 × 106 cells/ml in RPMI medium at pHs
7.5, 7, 6, and 4.5. Each inoculum was split in five subcultures
and complemented with 100, 50, 10 and 2 and 0 µg/ml Dox,
respectively. Cultures were then incubated for 24 h at 30◦C
under constant shaking. The next day, 50 µl of each culture
were transferred into the wells of a flat-bottom, half-area, black
microtiter plate. The plates were placed in a luminometer
(FLUOstar Omega, BMG Labtech, Ortenberg, Germany) and
50 µl of 2.5 µM water soluble CTZ injected prior to the
measurement of luciferase activity of each well.
Yeast Transformation
Yeasts were transformed by a lithium-acetate procedure as
previously described (Sanglard et al., 1996).
Pool Enrichment in Tolerant/Resistant
Strains
In order to enrich the pooled OE collection in FLC
tolerant/resistant isolates, strains were grown in RPMI 2%
glucose at pH 6 in the presence of 1 mM FeCl3 and with or
without 100 µg/ml Dox and 32 µg/ml FLC. To be as close as
possible to our drug susceptibility assay conditions (EUCAST
recommendations), cells were cultured in 96-well plates with
each well containing 200 µl of cell suspension in RPMI. Each
condition represents 20 ml of culture.
Briefly, a pool of the 572-strain collection was incubated
overnight in YEPD at 35◦C under constant shaking. The next day,
cells were centrifuged (5 min, 4600 rpm, 4◦C) and washed twice
with PBS. The cell pellet was resuspended at 107 cells/ml in RPMI
pH 6 and this inoculum was split into four 20 ml subcultures.
The remainders of the overnight culture were centrifuged and the
pellet frozen (−20◦C) prior to DNA extraction at the end of the
enrichment assay to estimate the initial population of our pool
(Day 0). The four subcultures were respectively complemented
with: (i) 32 µg/ml FLC, (ii) 100 µg/ml Dox, (iii) 32 µg/ml FLC
and 100 µg/ml Dox. The last subculture was the growth control
in which nor FLC or Dox were added. Each subculture was also
complemented with 1 mM FeCl3 to avoid the known synergistic
FLC-Dox effect (Fiori and Van Dijck, 2012). Two hundred
microliter of these subcultures were then transferred in each well
of 96-well plates, leaving two wells as contamination control. The
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plates were then incubated 24 h at 35◦C. Every day for the next
5 days, cells from the overnight culture in 96-well plates were
recovered using a multi-channel pipette and recovered into a
50 ml tube. The cultures were then processed as at Day 0. First,
the cells were centrifuged (5 min, 4600 rpm, 4◦C) and washed
twice with PBS and resuspended at 107 cells/ml in 20 ml fresh
RPMI in four new 50 ml tubes prior to addition of FLC, Dox and
FeCl3. The rest of the overnight cultures were centrifuged once
more and the pellet frozen (−20◦C) until DNA extraction.
Genomic DNA Extraction
Genomic DNA was prepared by spheroplasting from frozen cell
pellets according to Calabrese et al. (2000).
Amplification of the Barcodes
In order to estimate the strain presence in the different
populations, the BC of each cell was amplified by PCR to be
sequenced following the 16S Metagenomic Sequencing Library
Preparation protocol (Illumina, Inc., San Diego, United States)
recommendations to add so-called Illumina overhang sequences
to the amplicons (Supplementary File S3). However, to avoid
mistakes during the sequencing due to the similar flanking
regions of the BC amplicons, spacer bases (0, 4, 8, and 12 N)
were added to the forward primers to shift the signal during
sequencing (Supplementary File S3). Briefly, approximatively
12.5 ng of DNA extraction was used for BC amplification
using the Phusion High-Fidelity DNA Polymerase (New
England Biolabs, Ipswich, United States) following manufacturer
recommendations. The only modification to the preparation of
the samples was to use four forward primers instead of one
(Supplementary File S3), each diluted to a 1:4 ratio. The PCRs
were performed in a peqSTAR 2x thermal cycler (Peqlab-VWR,
Radnor, United States) with the following program: 3 min at
95◦C followed by 30 cycles at 95◦C, 57.9◦C and 72◦C for 30 s
each. A final elongation was performed for 5 min at 72◦C. To
increase the quality of our samples, the whole PCR products
were loaded on a 1% agarose gel for electrophoresis and bands of
interest purified using the NucleoSpin R© Gel and PCR Clean-up
kit (Macherey-Nagel, Düren, Germany) following manufacturer
recommendations.
Library Preparation and Sequencing
Library construction was performed at the Lausanne Genome
Technologies Facility (LGTF, University of Lausanne – Centre
for Integrative Genomics, Lausanne, Switzerland). Libraries
were prepared adapting the 16S Metagenomic Sequencing Library
Preparation protocol (Illumina) according to manufacturer
recommendations. MiSEQ Illumina 300 bp single-end
sequencing was performed on the libraries by the LGTF.
Barcode Quantification
The barcode quantification of the populations from the pool
enrichment assay was performed using a script developed by
Marion Patxot1. Each sequenced library was outputted as a
FASTQ file. To process the sequencing data, a bioinformatics
1https://github.com/dsanglard/Barcode-quantification-2.git
pipeline was set up using Perl programming language (v. 5.24.0)
and bash Shell (v. 3.2.57 for Mac OS X 10.11.16). Briefly, the
pipeline counts the occurrence of known barcode sequences in
a FASTQ file by running a MegaBLAST. There are two inputs to
the pipeline: the FASTQ file and a text file containing the name
and sequence of each barcode. Both files are first converted into
FASTA format. Each barcode sequence is then aligned to each
read in the FASTQ file. The alignment allowed 8 mismatches.
The pipeline outputs the occurrence of each barcode as a text file.
The sequence data was processed using the developed pipeline.
Counts for each time point and condition were merged into a
single text file with bash Shell. The proportion of each strain
in the population was subsequently calculated and plotted using
Open Source R Software (v. 3.2.4)2. In a second step, counts
were analyzed using the WT statistical guideline for DMS studies
described by Matuszewski et al. (2016). This approach calculates
a selection of coefficient estimators using the log ratios of
the number of counts for strains over the number of counts
for the reference.
RNA Extraction
RNA was extracted according to Amorim-Vaz et al. (2015).
Briefly, individual colonies of each tested strain were grown
overnight in YEPD medium at 30◦C under constant shaking
(220 rpm). Cultures were centrifuged (5 min, 4600 rpm, 4◦C)
and washed twice with PBS (137 mM NaCl, 10 mM phosphate,
2.7 mM KCl, and pH 7.4). Cell concentration was estimated
by spectrophotometry (OD540 nm) and cells were resuspended
at 5 × 105 cells/ml in distilled water. Hundred µl of this
suspension were next transferred into the wells of flat-bottom
96-well plates containing 100 µl of 2x RPMI (2% glucose)
complemented or not with 16 µg/ml FLC to obtain a final cell
concentration of 2.5 × 105 cells/ml and 8 µg/ml FLC per well.
Each tested condition corresponded to a whole 96-well plate and
represented approximatively 18.8 ml of culture in total. Plates
were incubated at 35◦C without shaking for 24 h. All nucleic acids
were extracted by mechanical disruption using glass beads and
phenol-chloroform separation as described previously (Amorim-
Vaz et al., 2015). The nucleic acids were stored at −80◦C prior
to DNase treatment. Genomic DNA was removed by DNase
treatment using the DNA-free DNA Removal Kit (Thermo-
Fisher Scientific) following manufacturer’s recommendation and
samples were stored at−80◦C.
RNA Sequencing and RNAseq Data
Mining
Library preparation and sequencing were carried out by the
LGTF and the sequencing was performed on an Illumina
HiSeq 2500 system (Illumina), using the TruSeq Stranded RNA,
125 bp single read protocol. The analysis was performed with
three biological replicates for each condition. RNAseq data
were processed using CLC Genomic Workbench Version 10.1.1
(Qiagen, Hilden, Germany). Reads were aligned to the C. albicans
SC5314 genome and read counts were normalized using the
quantile approach method. All conditions were compared with
2http://www.R-project.org/
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each other and filtered according to a specific statistical cut-off as
explained in the Results section. Raw data can be accessible under
the Bioproject numbers PRJNA638239 and PRJNA638870.
Software and Statistical Analysis
Graphics and statistical analysis were performed in GraphPad
Prism 7.03 (GraphPad Software, Inc., La Jolla, United States). The
online software Morpheus3 was used to create heatmaps for the
tolerance profile screening.
RESULTS
Optimizing Culture Condition for FLC
Tolerance Identification
Several techniques are available to establish the antifungal
susceptibility profiles of defined Candida isolates. Most of them
are based on drug diffusion assays in either a solid agar medium
or in liquid conditions, with each protocol having its specific
endpoint readout (Pappas et al., 2018). Despite having the same
purpose (i.e., identifying susceptible and resistant isolates), each
method has its advantages and flaws. Indeed, depending on the
Candida species and the tested drug, a given protocol might
be more optimal than another. A method for the identification
and quantification of tolerance to FLC on agar medium has
already been proposed (Gerstein et al., 2016). We here focused on
the identification of tolerance using standardized susceptibility
assays in microtiter plates (proposed by the EUCAST and
the CLSI) as it could be implemented and reproduced in
most laboratories.
We first performed drug susceptibility assays of several clinical
isolates known to exhibit FLC resistance and/or different residual
growth pattern (or “trailing”) in FLC susceptibility EUCAST
and CLSI tests with slight modifications. Trailing growth will
be now referred as a phenomenon related to tolerance. We
also performed FLC susceptibility assays at pH values of 7.5, 6,
and 4.5, since it has been reported that the pH of the culture
medium might influence the level of tolerance (Marr et al.,
1999). The results showed that both methods were comparable in
terms of strain categorization. The tested strains clearly exhibited
increased FLC tolerance when the growth medium turned acidic
(Supplementary Figure S1). The tested clinical isolates SSI 1489,
SSI 4622, and SSI 6028 could be categorized as susceptible in all
the tested conditions, as represented by their MICs below the
clinical breakpoint (CBP) of 4 µg/ml for FLC in C. albicans,
with the exception of isolate SSI 2503, which was known as FLC-
resistant (Supplementary File S1). Isolate SSI 5579 was more
ambiguous since its relative growth lied around the 50% relative
growth threshold at inhibitory FLC drug concentrations. Growth
reduction could still be observed at low FLC concentrations
(0–0.125 µg/ml FLC) and thus indicated that this strain might
not be considered as resistant, but rather as highly tolerant to
FLC. To summarize, each strain clearly exhibited a different
level of tolerance above the MIC, ranging from low values of
relative growth (1–2% as compared to drug-free control) to
3https://software.broadinstitute.org/morpheus
around 50% depending on the strain and the tested condition
(Supplementary Figure S2). We reflected these tolerance levels
by the use of a so-called tolerance index [TI = relative growth
(%)/100] based on growth measurement of the strains at a fixed
supra-MIC FLC concentration of 8 µg/ml (Figure 1).
To help distinguish between wild type, tolerant and resistant
isolates, we proposed to set TI thresholds. We first considered
that strains without decreased growth above the CBP as resistant.
On the other hand, we considered isolates as wild type when
residual growth above their MIC would not exceed 20% or
relative growth (TI < 0.2). Taking the results of Supplementary
Figure S1 as guides, we proposed to assign strains as tolerant
when their relative growth ranged between 20 and 80% (TI ≥ 0.2
and ≤ 0.8). Even though these TI thresholds are not based on
the occurrence of molecular markers of tolerance, which are
still to be discovered, they still allow a discrimination between
phenotypes that will be useful in this study by using a single
FLC concentration (8 µg/ml) to facilitate strain comparisons and
large-scale screenings.
Application of the Tolerance Assay for
the Identification of Tolerant Strains
To confirm the efficiency of the TI to identify tolerant strains,
we next performed a large screening of C. albicans clinical
isolates from different origins (n = 181) including isolates with
known acquired azole resistance mechanisms. Data summarized
as a heat map in Figure 2 show that 5 major categories of
phenotypes could be distinguished according to the obtained TIs.
A first category (Figure 2, category 1) contained mainly azole-
resistant strains above the 0.8 threshold TI value at all tested pH
values. Since the majority of these strains contain known azole
resistance mechanisms (Supplementary File S1), this validates
the selection of the TI threshold value at 0.8 for azole-resistant
strains. A second category (Figure 2, category 2) contained
isolates exhibiting tolerance at specific pHs. A third category
(Figure 2, category 3) contained isolates exhibiting tolerance
at low pH (pH 4.5). A fourth category (Figure 2, category 4)
contained azole-susceptible isolates with wild type characteristics
(TI threshold ≤ 0.2). The last and fifth category contained
isolates exhibiting tolerance at high pHs only (pH 7.0–7.5). No
correlations were identified between clade assignments of tested
strains and TI profiles. The diversity in FLC tolerance patterns
suggests that multiple tolerance mechanisms could be involved.
Gene Overexpression Strategy for the
Identification of FLC Tolerance
Mediators
In order to identify genes involved in FLC tolerance, we chose
a gene overexpression strategy. To achieve this purpose, a 572-
strains collection reported in Chauvel et al. (2012) and Znaidi
et al. (2018) was used, with each strain overexpressing a specific
gene on a Dox-dependent manner. Briefly, the OE system consists
of two distinct plasmids. First, a vector (pNIMX) expressing
the Tetracycline (TET)-binding transactivator (TA) under the
control of the TDH3 promoter (PTDH3) was introduced in the
parental strain CEC161, which is derived from BWP17, yielding
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FIGURE 1 | Comparison of CLSI and EUCAST protocols for the identification of tolerant isolates. Comparison was performed at pHs 7.5, 6.0, and 4.5 (A–C,
respectively) to assess the pH effect upon tolerance as stated by Marr et al. (1999). (D) Represents the correlation between both approaches with the respective R2
corresponding to each tested pH (Two-tailed Pearson correlation. confidence interval = 95%). Each bar corresponds to the mean of biological duplicates. Statistical
significance was calculated using Sidak’s multiple comparison tests (two-way ANOVA, 95% confidence interval). P-values: <0.0001 (****).
FIGURE 2 | FLC tolerance screen of 181 C. albicans strains. The heatmap represents the mean TI values of at least 2 biological replicates. The “susceptible” and
“non-susceptible” categories of the legend are based on the EUCAST definitions. Detailed results can be found in Supplementary File S1. Heatmap was generated
with Morpheus (https://software.broadinstitute.org/morpheus/) with Euclidian distance metrics and average linkage method including hierarchical clustering on TI
values and pH conditions. Red labeled isolate names correspond to isolates with known azole resistance mechanisms (Supplementary File S1).
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strain CEC2097 (Chauvel et al., 2012). Next, the CIp10-PTET
plasmid collection (572 plasmids), with each plasmid expressing
a gene of interest (GOI, listed in Supplementary File S2) under
the control of a TET-inducible promoter (PTET) was introduced
in CEC2097. These second plasmids also bear specifics 20 bp tags
(or barcodes, BC) allowing their identification by sequencing,
thus facilitating the design of pool experiments. In this work, the
pooled strains were subjected to FLC selection in the presence
of doxycycline (Dox). Under these conditions, strains expressing
genes mediating tolerance may be favored over those with wild
type characteristics.
Prior to selection experiments with this collection of pooled
strains, optimal OE conditions had to be determined. We
chose to grow the C. albicans OE collection in RPMI medium
to be consistent with EUCAST culture conditions. It was
necessary to determine at which Dox concentration a significant
OE could be detected. To address this question, a Dox-
dependent Gaussia princeps luciferase (gLUC) reporter strain
(CEC3083) was used. This strain was used to determine the
optimal pH and Dox concentration for the pool enrichment
assay (Supplementary Figure S2). The luminescence signal
became saturated at 100 µg/ml Dox and at both pH 7 and
7.5. The medium pH also influenced the level of detected
luminescence. At pH 4.5, the signal was at least 10-fold lower
compared to the other pH conditions and independently of the
Dox concentration. Luminescence signals resulting from Dox
addition appeared similar between pHs 6.0, 7.0, and 7.5. Thus,
with these observations, pH 6.0 and 7.0 seemed optimal for gene
OE. It is also known that Dox acts synergistically with FLC,
converting this drug into a fungicidal rather than fungistatic
drug. This synergistic effect is due to the ability of Dox to chelate
iron but can be reversed by addition of iron (FeCl3) in the
medium (Fiori and Van Dijck, 2012).
Enrichment in Resistant/Tolerant OE
Strains in Pool Assay and Single Profiling
In order to identify new mediators of tolerance using the OE
collection, an enrichment in tolerant strains from a pool was
performed. Briefly, the 572 strains were pooled and grown under
strong FLC pressure (32 µg/ml) and in the presence or absence of
Dox (100 µg/ml) at pH 6.0. To select tolerant strains, the culture
was maintained for 5 days with daily re-inoculation into fresh
media to maintain FLC and Dox concentrations. After 5 days
of subculture, the fraction of each strain in the population was
estimated for each tested condition by sequencing of the BC.
To evaluate the effect of this prolonged culture on the evolution
of population, the BC population of the fifth day (D5) in the
absence of Dox and FLC [D5 (D−F−)] was compared to the
initial population (D0). The mean ratio D5 (F-D-)/D0 measured
for all strains was 0.99 (Figure 3A), suggesting that strains were
represented in the same proportion at D5 and D0 and confirming
that fluctuations in populations at D5 are due to the different
growth conditions (Figure 3A, top line). To evaluate the effect
of FLC and Dox, the proportion of each strain in the presence
of both compounds [D5 (D+F+)] was compared to the reference
condition [D5 (D−F−)] (Figure 3A, second line). Strains were up
to 600-fold enriched and 25-fold depleted in the presence of FLC
and Dox as compared to the reference (Supplementary File S2).
Comparison of the population in the presence of FLC only [D5
(D-F+)] to the reference allowed the identification of intrinsically
resistant/tolerant strains with strains up to 900-fold enriched
in presence of FLC and highly sensitive strains which were
up to 15-fold depleted (Figure 3A, third line, Supplementary
File S2). To determine the effect of Dox in the absence of
FLC on the population, the population in presence of Dox
only [D5 (D+F−)] was compared to the reference condition.
Here, strains were up to 15-fold enriched and up to 500-fold
depleted at D5 (D+F−), indicating a slight effect of Dox on the
population which is probably linked to the non-tightly regulated
OE system (Figure 3A, fourth line, Supplementary File S2).
Finally, the effect of Dox in presence of FLC was estimated
by comparing the population D5 (D+F+) to the population
D5 (D−F+) (Figure 3B, bottom line). This last comparison is
expected to give valuable insight into the genes that mediate a
selective growth advantage in the population when overexpressed
in presence of FLC. In this comparison 78 strains were at
least 2-fold enriched and 39 strains 2-fold depleted when their
respective genes were overexpressed under strong FLC pressure
(dotted line of Figure 3B and Supplementary File S2). Among
them, the three top strains were those overexpressing GZF3,
orf19.399, and CRZ1 (60-fold, 38-fold, and 25-fold enriched,
respectively) (Table 1). On the other hand, the three strains
which were the least represented in the pool were the strains
overexpressing orf19.2097, SFL2 and CPH1 (18-fold, 11-fold, and
9-fold depleted, respectively) (Figure 3B and Table 1).
To avoid a bias caused by growth in pools and to confirm
the candidate genes identified in the pool enrichment procedure,
the tolerance profile of each strain in the collection was tested
individually (Figure 4). Growth in the presence of FLC and
Dox (D+F+) and in the presence of FLC only (D−F+) were
compared to growth in the F−D− control condition. Relative
growth in the presence of Dox and FLC (D+F+) ranged
from 14 to 67% as compared to the F−D− control condition,
while relative growths under FLC pressure only (D−F+) was
comprised between 8 and 65% (Supplementary File S5). In
order to select tolerant/resistant strains, isolates with a relative
growth at least 2-fold higher in the presence of Dox and FLC
(D+F+) than in presence of FLC only (D−F+) were selected
(Figure 4A and Supplementary File S2). Interestingly, unlike
results obtained from the pool enrichment assay (78 strains
at least 2-fold enriched), only four strains exhibited a 2-fold
increase of growth in presence of FLC and Dox in the single
strain assay (Figure 4B). This suggests a pool effect in the
pool enrichment assay, which may be due to the duration
of the pool experiment (5 days). These four strains included
those overexpressing GZF3 (2.14-fold growth increase), YVH1
(2.05-fold increase), PTC2 (2.02-fold increase), and YCK2 (2.01-
fold increase) (Figure 4B and Table 2). On the other hand,
no strains exhibited relative growth at least 2-fold reduced
when Dox was added. Indeed, only the strain overexpressing
CSK1 showed a decreased growth in presence of Dox (0.52-fold
decrease), but this growth depletion was due to an abnormal
high growth (65% of the growth control) when grown in
Frontiers in Microbiology | www.frontiersin.org 8 November 2020 | Volume 11 | Article 591140
fmicb-11-591140 November 6, 2020 Time: 11:49 # 9
Delarze et al. Candida albicans Azole Tolerance
FIGURE 3 | Comparisons of the population of the 572-Tet-inducible OE strains collection pool after 5 days of enrichment. (A) The heatmap represents the
comparison between the cultures at day 5 (D5) and the initial population (D0), in presence (F+) or absence (F–) of FLC (32 µg/ml), and in the presence (D+) or
absence (D–) of 100 µg/ml Dox. Each line represents the mean relative count ratio of biological duplicates. The heatmap is filtered based on the [D5 (D+F+)/D5
(D–F+)] comparison. (B) Enrichment of specific Tet-dependent OE strains in the presence of FLC with and without Dox. The dotted line represents a 2-fold threshold
enrichment between FLC exposed cells in the absence and presence of Dox. Y-axis is in log2 scale. Detailed data can be found in Supplementary File S2.
presence of FLC only (Figure 4). The difficulty to observe growth
reduction upon Dox induction in presence of FLC might be
due to the already low tolerance level of the parental CEC161
strain used to build the collection. Interestingly, the GZF3
OE strain was the best hit in both pooled and single assays
approaches, making it an engaging potential mediator of FLC
tolerance. Using results from both the enrichment and the single
strains assays, a total of twelve strains were selected for further
characterization of their FLC susceptibility and tolerance profile
including the strains overexpressing GZF3, CRZ1, PTC2, YVH1,
YCK2, orf19.399, orf19.5157, orf19.2320, SGS1, ASF1, UBA4,
and ZCF21.
Positive Regulators of FLC Tolerance
Given that the genetic background of the C. albicans BWP17-
derived strain used in the previous screenings exhibits low
FLC tolerance, this made difficult to address potential negative
regulators of FLC tolerance. We rather focused on positive
putative positive tolerance regulators. The 12 selected isolates of
the OE collection including the wild type SC5314 were re-tested
individually to establish their FLC susceptibility profiles at pH 6.0
in the presence of Dox (Figure 5). At this Dox concentration, all
strains exhibited similar MIC independently of Dox induction,
with all MICs remaining at around 0.125 µg/ml FLC. FLC
tolerance was assessed by TIs at the fixed FLC concentration of
8 µg/ml and by comparing TIs in the absence and presence of
Dox. In this assay, significant increase of TIs in the presence
of Dox was only obtained in the strains overexpressing GZF3
(TI = 0.048–0.2), CRZ1 (TI = 0.07–0.21) and YCK2 (TI = 0.06–
0.14). CRZ1 is a calcineurin-regulated transcription factor already
identified to play a role in FLC tolerance by Onyewu et al. (2004)
and Karababa et al. (2006) and recently by Rosenberg et al.
(2018). GZF3 is a putative GATA-type transcription factor, of
which the Saccharomyces cerevisiae ortholog negatively regulates
nitrogen catabolic gene expression (Soussi-Boudekou et al.,
1997). YCK2 encodes a plasma membrane protein similar to the
S. cerevisiae casein kinase I, which is required for the membrane
trafficking of Pdr5 (the ortholog of the multidrug transporter
CDR1 in S. cerevisiae) to the cell surfaces (Decottignies et al.,
1999). The re-identification of CRZ1 here underscores that the
selection of FLC mediators by the undertaken experimental
approaches is feasible, even if limitations have to be considered
(see below).We focused next only on CRZ1 and GZF3, since
the Dox-dependent overexpression of these genes in C. albicans
reached the threshold of tolerance (TI ≥ 0.2) that we previously
defined for clinical isolates.
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TABLE 1 | Top 10 enriched and depleted strains after 5 days of subculture.
orf n◦ Gene name (D−F−)1/D0 2 D5 2 (D+F+)/(D−F+) Category
Top 10 enriched strains orf19.2842 GZF3 1.07 60.60 Transcription factor
orf19.399 NA3 1.08 38.63 Protein kinase
orf19.7359 CRZ1 1.07 25.87 Transcription factor
orf19.5157 NA 1.18 9.43 Protein phosphatase
orf19.5335 SGS1 1.36 9.36 DNA replication/recombination/repair
orf19.3715 ASF1 0.96 8.07 DNA replication/recombination/repair
orf19.2324 UBA4 1.25 7.73 Protein phosphatase
orf19.4166 ZCF21 1.14 6.93 Transcription factor
orf19.2320 NA 1.41 6.86 Protein kinase
orf19.2907 PGA42 1.14 6.21 Cell wall gene
Top 10 depleted strains orf19.217 NA 0.81 0.30 Transcription factor
orf19.4979 KNS1 1.38 0.25 Protein kinase
orf19.3300 ZPR1 0.43 0.21 Transcription factor
orf19.1189 NA 0.99 0.20 DNA replication/recombination/repair
orf19.6936 RAD53 0.99 0.15 Protein kinase
orf19.7208 CSK1 0.97 0.14 Protein kinase
orf19.5032 SIM1 0.26 0.13 Various
orf19.4433 CPH1 0.86 0.11 Transcription factor
orf19.3969 SFL2 0.87 0.09 Transcription factor
orf19.2097 NA 0.83 0.05 Transcription factor
The effect of 5 days of subculture [D5 (D−/F−)/D0] and the effect of the gene OE in presence of FLC [comparison with the initial pool population (D5 (D+/F+)/(D−/F+))] on
the pooled population is represented as the fold change of the presence of a strain in the population. 1D, doxycycline; F, fluconazole, +/-, presence/absence of the drug.
2D0, initial population (Day 0); D5, population after 5 days on enrichment. 3Not available.
CRZ1 and GZF3 OE in Deletion Mutants
In order to better understand the mechanisms behind tolerance
and the potential relation between CRZ1 and GZF3, each
gene was overexpressed in single and double mutants. For
this purpose, a crz11/1, gzf31/1 double mutant (EDY28-2,
Supplementary Table S1) was constructed using the crz11/1
mutant from the Homann’s deletion mutant collection (Homann
et al., 2009). The OE system for either CRZ1 or GZF3 was then
transformed in this double mutant, in both Homann’s crz11/1
and gzf31/1 single mutants as well as in the parental WT
strain of the Homann’s collection. A control plasmid (CIp10-
PTET-GTW, Supplementary Table S1) was also transformed in
each strain as control of the OE system. The FLC susceptibility
profiles of these strains were then established in presence or
absence of Dox and FLC to assess their respective MICs and TIs
(Figures 6A–D). These susceptibility assays were performed at
pHs 6.0 and 7.0.
Overall, all strains exhibited similar MIC values in presence or
absence of Dox. The MIC for all tested strains at pH 7.0 was equal
to 0.0625 µg/ml FLC with negligible variation. The gzf31/1
mutant overexpressing CRZ1 showed the highest increase in
MIC value, reaching 0.25 µg/ml FLC in presence of Dox
(Figures 6A,C). Globally, the susceptibility profile remained the
same at pH 6.0. With regards to FLC tolerance, all strains showed
a basal TI under the lower tolerance threshold (i.e., TI = 0.2) at
both pH values in absence of Dox. Consistent with observations
of the pool enrichment assay, CRZ1 and GZF3 OE resulted in a
significant increase of the TI in a WT background. In gzf31/1
mutants, significant increase in TI could be observed at both
pHs under CRZ1 and GZF3 OE. Indeed, TI increased from 0.17
to 0.28 and 0.16 to 0.31 at pH 7.0 and from 0.07 to 0.13 and
0.07 to 0.14 at pH 6.0 for CRZ1 and GZF3 OE, respectively
(Figures 6B,D). On the other hand, only CRZ1 OE resulted in an
increased in tolerance in the double crz11/1, gzf31/1 mutant.
No effect of GZF3 OE on tolerance could be observed in the
crz11/1 mutant as well as in the double crz11/1, gzf31/1
mutant (Figures 6B,D). However, CRZ1 OE in these mutant
backgrounds resulted in increased tolerance at pH 7.0 and 6.0,
respectively (Figures 6B,D).
To summarize, our results indicate that overexpressing CRZ1
results in increased FLC tolerance in all mutant backgrounds
but, on the other hand, GZF3 OE increases tolerance only when
CRZ1 was present. These results suggest that CRZ1 controls the
expression of one or more intermediary proteins or cofactors
necessary for GZF3 activity, which in its turn could activate other
regulators of tolerance. Taking the hypothesis that CRZ1 and
GZF3 may be part of a same pathway, our results indicate that
GZF3 may act upstream of CRZ1.
CRZ1 and GZF3 Deletions in Tolerant
Clinical Isolates
To confirm the role of CRZ1 and GZF3 in promoting
tolerance to fluconazole not only in laboratory strains,
either one or both allele of each gene was deleted in the
C. albicans clinical isolates DSY2110, DSY4454, SSI 4622 and
DSY4588, already known to exhibit different level of FLC
tolerance (Supplementary Figure S3). Revertant strains were
constructed by reinsertion of CRZ1 and GZF3 alleles from
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FIGURE 4 | Single strain tolerance profiling. (A) Heatmap representing the relative growth of the 572 Tet-inducible OE BC strains collection at pH 6, in presence of
32 µg/ml FLC pressure (F+) and in presence (D+) or absence (D–) of 100 µg/ml Dox. Each line represents the mean relative growth of biological triplicates. (B) Effect
of Dox induction upon FLC tolerance represented as the growth ratio between the condition with and without Dox [(D+F+)/(D–F+)]. Specific genes above a ratio of
2-fold relative growth increase (dotted line) and below a ration of 1.0 are indicated. Detailed data can be found in Supplementary File S2.
FIGURE 5 | Susceptibility profiles of selected Tet-inducible strains in the presence Dox. Susceptibility profiles were performed at pH 6, in a range of FLC
concentrations (0–16 µg/ml), in the presence (Dox+) or absence (Dox–) of doxycycline at 100 µg/ml and complemented with 1 mM FeCl3. FLC susceptibility was
presented by their modal MIC value (left panel) and TIs at 8 µg/ml FLC (right panel). Standard deviations of the MIC values were calculated based on the mean MIC
of each sample. The horizontal dashed line represents the lower threshold of tolerance (TI = 0.2) and the limit of susceptibility (TI = 0.5) as defined by EUCAST. Each
bar is representative of biological triplicates. Statistical significance was determined using Sidak’s multiple comparison tests (Two-way ANOVA, Confidence
interval = 95 %). P-values: (****) ≤ 0.0001.
the reference isolate SC5314. The FLC susceptibility profiles
of each mutant and associated parental clinical isolates were
assessed at pHs 7.5, 7.0, 6.0, and 4.5 and their MIC values
and TIs extracted for comparisons. Globally, no differences
could be observed between the MIC values of the original
clinical isolates and their respective mutants, with all MICs
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TABLE 2 | Listing of the 10 top-hit strains showing the highest and lowest growth ratio in the single strain FLC tolerance assay.
orf n◦ Gene name Relative growth (% GC)1 Fold change (−)
D−F+2 D+F+ (D+F+)/(D−/F+) Category
Top 10 strains orf19.2842 GZF3 12.44 26.35 2.14 Transcription factor
with increased orf19.4401 YVH1 9.67 19.82 2.05 Protein phosphatase
tolerance orf19.2538 PTC2 12.75 25.43 2.02 Protein phosphatase
orf19.7001 YCK2 14.03 28.24 2.01 Protein kinase
orf19.3356 ESP1 11.32 22.34 1.97 DNA replication/recombination/repair
orf19.5144 PGA28 11.61 22.87 1.97 Cell wall gene
orf19.6792 RRD1 13.17 25.83 1.96 Protein phosphatase
orf19.799 STE4 13.06 25.42 1.95 Other signaling comp
orf19.5636 RBT5 10.36 20.09 1.94 Cell wall gene
orf19.5257 LCB4 14.57 27.58 1.94 Various
10 strains orf19.3199 PIKA 13.76 17.56 1.32 Various
ranking last in orf19.3294 MBF1 13.47 17.61 1.31 Transcription factor
the TI screen orf19.1759 PHO23 18.91 24.34 1.31 Transcription factor
orf19.4377 KRE1 16.48 20.01 1.28 Cell wall gene
orf19.4473 NA3 55.66 67.60 1.24 Uncharacterized
orf19.7652 CKA1 17.28 19.70 1.23 Protein kinase
orf19.6926 CSC25 13.31 15.76 1.20 Protein kinase
orf19.3589 SPO11 14.05 16.82 1.20 DNA replication/recombination/repair
orf19.7473 NA 53.59 63.65 1.18 DNA replication/recombination/repair
orf19.7208 CSK1 65.37 34.08 0.52 Protein kinase
1% of the drug free growth control. 2D, doxycycline; F, fluconazole, +/−, presence/absence of the drug. 3NA, not available.
standing below the FLC clinical breakpoint (CBP) of 4 µg/ml
(Supplementary Figure S4).
When inspecting variations of FLC tolerance in the generated
mutants and revertants, a general trend was that deletion of CRZ1
reduced tolerance levels in all tested strains (for convenience only
data from pH 6.0 and 7.0 measurements are shown in Figure 7,
all pHs are shown in Supplementary Figure S5). Only for strain
DSY4488, the deletion of GZF3 produced little but significant
reduction of FLC tolerance at pHs 6.0 and 7.0 as compared to
the initial clinical strain. Reversion of the gene deletions by wild
type CRZ1 and GZF3 alleles from SC5413 at their genomic loci
was not always resulting in initial tolerance levels. For example,
CRZ1 restoration in the background of the crz11/1 mutant of
DSY2110 did not revert tolerance to the levels of the wild type
clinical strains as well as hetero- and homozygous CRZ1 mutants.
We confirmed by another phenotypic test (SDS susceptibility,
Supplementary Figure S6) that the CRZ1 revertant could
complement the mutant phenotypic defects, showing that the re-
introduced CRZ1 allele was still functional. Taken together, the
results of CRZ1 and/or GZF3 deletions and reversions revealed
that CRZ1 was the factor that most prominently altered FLC
tolerance of the clinical stains. The results were dependent on the
tested pHs and on the genetic background of the isolates.
Transcriptomic Imprints of FLC
Response in FLC-Tolerant Clinical
Isolates
As shown earlier, clinical strains exhibit several degrees of FLC
tolerance. One alternative approach to address the mechanisms
behind the development of FLC tolerance is to compare
transcriptional profiles between strains exhibiting different FLC
tolerance levels. It was of interest to address the transcriptional
profile of such strain in the presence of FLC under the conditions
in which tolerance was tested. Given that the best option
of comparisons is between related isolates, we inspected our
strain collection for related strains exhibiting different FLC
tolerance profiles. The chosen strains were originating from
a group of related strains including DSY4454, DSY4452 and
DSY4588. These strains were recovered from a patient suffering
of endocarditis which was treated for an extensive period with
FLC (8 years). DSY4454 was the earliest strain recovered (year
2005) from the patient, while DSY4588 was the latest (year
2013). Patient and sampling details are given in Supplementary
File S6 and FLC tolerance profiles in Supplementary Figure
S7. DSY4454 exhibited low TIs at all pHs (except at pH 4.5),
while DSY4452 and DSY4588 were showing TIs above the 0.2
threshold value at neutral pHs. The relationship between strains
was investigated with Multi Locus Sequence Typing (MLST,
Supplementary File S6) (Gow et al., 2003). A single loss of
heterozygosity (LOH) event was detected in the SYA1 allele
of isolate DSY4588 as compared to the other strains, thus
suggesting that micro-evolution between the strains could have
occurred. However, the MLST results indicated that the strains
were from the same type, thus suggesting a strong genetic
relationship between them.
RNAseq analysis was carried out as described in section
“Materials and Methods.” The isolate SC5314 was included in
these RNAseq analysis as a control isolate exhibiting low level of
tolerance (Supplementary Figure S7). Gene expression changes
were extracted by pairwise comparison between conditions
with and without FLC. The data were filtered for significance
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FIGURE 6 | Susceptibility profile of the CRZ1 and GZF3 mutants overexpressing either CRZ1, GZF3. (A,C) Susceptibility to FLC is represented as the modal MIC
value with standard deviation calculated on the mean MIC of all replicates. (B,D) Tolerance profile of the mutant strains. The mean TI and standard deviations are
represented. Horizontal dashed lines represent the lower threshold of tolerance (TI = 2), and the upper limit of susceptibility (TI = 0.5) as described by EUCAST. Each
data set represents the mean (or mode) of biological duplicates. Statistical significances (B,D) were estimated using Sidak’s multiple comparison tests (two-way
ANOVA, 95% confidence interval) between Dox– and Dox+ conditions in the same mutants set. P-values: (****) ≤ 0.0001. Supplementary Table S1 lists
correspondence between genotype and strain number.
(False Discovery Rate, FDR ≤ 0.05) and for expression change
(≥2-fold) between drug-exposed and non-exposed conditions
(Supplementary File S7). The filtered data are summarized
in Table 3. The FLC-regulated genes from the clinical strains
DSY4452, DSY4454, DSY4588 and SC5314 were next subjected to
Gene Set Enrichment Analysis (GSEA) using a database of gene
list originating from 307 published studies (Supplementary File
S8). This database includes conditions in which (i) C. albicans was
exposed to different antifungal agents, (ii) C. albicans mutants
were exposed to different growth conditions, (iii) C. albicans
was exposed to host cells and (iv) C. albicans was grown
in vitro under conditions mimicking host environments. The
GSEA list also contains C. albicans genes with binding sites for
several transcription factors. In general, the used conditions are
divided into lists of up-and down-regulated genes. The software
compares a query list of up- and down-regulated genes with
existing gene lists and identifies those that overlap through
statistical evaluation. A network of associated gene lists can be
formed using visualization software such as Cytoscape (GSEA
enrichment map) depending on the overlaps between conditions.
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FIGURE 7 | Tolerance levels of the different deletion mutants for both CRZ1 and GZF3 in the DSY2110, DSY4454, SSI 4622, and DSY4588 genetic backgrounds at
pHs 6.0 and 7.0. Each bar corresponds to at least biological duplicates. Statistical significance was calculated using Turkey multiple comparison tests (95%
confidence interval). P-values: 0.1234 (ns), ≤0.0332 (*), ≤0.0021 (**), ≤0.0002 (***), ≤0.0001 (****). Blue stars correspond to the comparison with the parental clinical
isolates (blue bars). Black stars correspond to the comparisons between related mutant strains. Supplementary Table S1 lists correspondence between genotype
and strain number.
TABLE 3 | Genes regulated by FLC in the clinical strains.





These data are summarized in Figure 8 (for simplicity only the
GSEA map for DSY4452 is shown).
The GSEA map for DSY4452 highlights several features
which can be also observed in the maps of the other isolates
(Supplementary Figure S8). First, the genes regulated by FLC
in the clinical isolates overlapped as expected with published
datasets in which C. albicans was exposed to FLC in different
growth conditions. The connected nodes “FLUCONAZOLE_UP”
and “FLC3H_UP” were overlapping with most FLC-upregulated
genes in the clinical strains. “FLUCONAZOLE_UP” data
originate from a study (Vasicek et al., 2014) in which C. albicans
was exposed for 6 h in the presence of 10 µg/ml FLC
in YEPD at 30◦C. “FLC3H_UP” data are from a study
(Keller et al., 2015) in which C. albicans was treated with
0.5 µg/ml FLC for 3 h in RPMI medium at 37◦C. All
these experiments were performed under agitation in liquid
cultures. Considering that most FLC-downregulated genes are
also found in the nodes “KETOCONAZOLE_DN,” “FLC3H-
DN,” and “FLUCONAZOLE_DN,” the results obtained here are
consistent with already published transcriptional data of FLC-
exposed cells.
When looking at FLC-upregulated genes, the GSEA
data of DSY4452 contained clusters of nodes related to
the calcineurin pathway (CALCINEURIN,” “CNA_CRZ1”
and “CNA 20 min_up”). Strikingly, these nodes were
connected to those originating from FLC-exposed conditions
(“FLUCONAZOLE_UP,” “KETCONAZOLE_UP,” “FLC3H_UP”)
and from nodes of transcription factors controlling sterol
homeostasis (“UPC2_UP”). These networks, containing genes
positively regulated by FLC, were also associated with a node
comprising genes upregulated by UPC2 with a gain of function
mutation (“UPC2_G648D_UP”) (Dunkel et al., 2008). This
underlines the importance of this transcription factor in azole
response. Taken together, these data suggest that the calcineurin
pathway is connected to the response of C. albicans to FLC,
which is consistent with the connection made above between
CRZ1 and FLC tolerance.
In order to identity potential mediators of tolerance in
the set of clinical strains, the expression of which could
vary between wild type (DSY4454) and FLC-tolerant isolates
(DSY4452 and DSY4588), the ratios of FLC-regulated genes
were determined between pairs of isolates. Expression ratios
were first calculated between DSY4452 and DSY4454 and
between DSY4588 and DSY4454 (Supplementary File S8).
Significant fold-changes were selected between these conditions
(p-values ≤ 0.05) and the data were filtered with a 2-fold
change in expression as cut-off. The expression ratio between
DSY4452 and DSY4454 was changed by more than 1.5-fold
for 41 genes (Supplementary File S9). Interestingly, 12 out
these 41 genes were regulated by calcineurin and/or CRZ1.
Moreover, the expression ratios of these 41 genes between
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FIGURE 8 | GSEA enrichment map of FLC regulated genes in clinical isolate DSY4452. Analysis parameters were as follows: norm, meandiv; scoring_scheme,
weighted; set_min, 15; nperm, 1000; set_max, 500. GSEA results were uploaded into Cytoscape 3.0 with the following parameters: P-value cutoff, 0.01; FDR
q-value, 0.05. Red nodes represent enriched gene lists in upregulated genes from the GSEA. Blue nodes represent enriched gene lists in downregulated genes from
the GSEA. Nodes are connected by edges when overlaps exist between nodes. The size of nodes reflects the total number of genes that are connected by edges to
neighboring nodes. Edge thickness reflects the level of confidence between nodes.
DSY4588 and DSY4454 were above the 1.5-fold threshold. These
results suggest a conservation of the FLC response between
the tolerant strains DSY4452 and DSY4588 as compared to
DSY4454. Intriguingly, most of the ratios of the 41 above-
mentioned genes between DSY4454 and SC5314, both of which
could be considered as “wild type” in terms of FLC tolerance,
were below the 1.5-fold threshold. Taken together, the data
presented here suggest that the expression of genes that are
known to be calcineurin- and/or CRZ1-dependent is increased
in the FLC-tolerant clinical strains and this indicates that the
calcineurin pathway is modified by still uncharacterized factors
in these strains.
DISCUSSION
In this study, we aimed to better define FLC tolerance and
to identify FLC tolerance mediators in C. albicans. The term
of tolerance is too often confounded with the description
of drug resistance in published studies. We first addressed
adequate methods for the quantification of FCL tolerance
in order to facilitate comparisons between different isolates.
Standardized microdilution susceptibility assays that include
CLSI and EUCAST protocols are widely used to assess
antifungal susceptibility of fungi. We took advantage of these
established assays to measure FLC tolerance. However, since
the EUCAST protocol integrates the use of optical density
measurements as readouts, this protocol was chosen as an assay
to quantify tolerance in C. albicans. In principle, the assay
consists in measuring optical density in microdilution plates
at a fixed FLC concentration (8 µg/ml) above the CBP MIC
threshold of 4 µg/ml FLC and to express growth as a relative
value (from 0 to 1), which we called as “tolerance index”
(TI). Recently, an alternative tolerance assay was published
that used static growth conditions on disk diffusion assays
with agar plates. Growth inside the inhibition zone was
quantified and served as a basis to quantify FLC tolerance
(Rosenberg et al., 2018).
Using a large collection of C. albicans isolates, among
which some were genome-sequenced, the measured TIs enabled
to split isolates into 3 major categories. The first category
included isolates with TI values ≤ 0.2 and were ranked
as wild type FLC-susceptible isolates. The second category
included isolates with TIs values > 2 and <0.8. These isolates
were considered as FLC-susceptible but FLC-tolerant. The
third category included isolates with TIs values ≥ 0.8 and
included isolates ranked as FLC-resistant. This categorization
was consolidated by the fact that most isolates with TI > 0.8
were exhibiting known azole-resistance mechanisms (Figure 2).
The TI threshold value of 0.2 for distinction between wild
type and tolerant isolates is less obvious to consolidate by the
occurrence of specific mechanisms, since tolerance mechanisms
are not yet associated with specific gene mutations However,
this threshold enables to discard a dominant population of
isolates that have wild type characteristics in the query of
tolerance mechanisms.
One of the observations made in the tolerance assays is
that there was a pH-dependent effect in tolerance profiles.
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Using a specific subset of isolates, we observed that acidic
pH increased FLC tolerance (Figure 1). An opposite tendency
(decreasing tolerance with decreasing pH) was reported earlier
by Marr et al. (1999) and more recently by Rosenberg et al.
(2018). It is not clear as to why our results differ from these
published results. The methods used in these studies referred to
minimal and complex culture media and to agar diffusion assays,
respectively. Thus, one might argue that these assay conditions
could have impacted on the obtained results. Since different
isolates were used in these different studies, it is difficult to
identity the cause of such disagreements. Our own results with
RPMI and YEPD media in FLC tolerance assays indicate that
the use of YEPD -similar to the medium used by Rosenberg
et al. (2018)- results in a drop of FLC tolerance at low pH
in some strains, but not all of them, as compared to RPMI
(Supplementary Figure S9). This suggests that the medium
composition is an important variable in FLC tolerance assays,
however, the genetic background of the tested strains may also
contribute to this variable. This is in agreement with results
of Figure 2 gathering TIs of a large set of strains highlight
that the pH dependency of FLC tolerance is a rather strain-
dependent attribute, since about 70% of tested isolates (categories
4 and 5) do not exhibit an increase of FLC tolerance at low
pH in RPMI. Another study was published by Luna-Tapia et al.
(2015) in which a VSP21 mutant exhibited high tolerance to
FLC at both pH 7.0 and pH 3.0. In this work, a CLSI protocol
was used which therefore was more closely related to the
conditions tested here. Luna-Tapia et al. (2015) demonstrated
that tolerance of the VSP21 mutant was decreased at pH 3.0
compared to neutral conditions. While these data support pH
dependency on FLC tolerance, the results used a specific mutant
which might trigger pH-specific response and might differ from
clinical wild type isolates. Thus, pH dependency of FLC tolerance
remains controversial.
We next addressed the identification of FLC tolerance
mediators using a forward genetic screen with a pool enrichment
approach using a collection of 572 barcoded strains. This strategy
used the RPMI medium and growth conditions used to determine
tolerance in clinical strains. Each of these strains overexpressed
a specific gene under the control of Dox (Chauvel et al., 2012).
The same set of pooled strains was used by Znaidi et al.
(2018) in a genetic screen performed in a murine model of
gastro-intestinal colonization. In this study, the authors used
the barcodes to identify strains of interest that were enriched
and/or depleted in the animal model in the presence of Dox.
Different from the barcode sequencing system used in the
present study, Znaidi et al. (2018) used a barcode detection
system based on microarrays on which all barcode tags were
deposited. In the animal model selection system, only one gene,
CRZ2, was identified as conferring a selective growth advantage
when overexpressed in the animal gut. CRZ2 encodes a zinc
finger transcription factor of the C2H2 family that is similar
to the calcineurin target Crz1p, however, it is not involved
in calcium signaling (Karababa et al., 2006). In the present
study the pooled collection was maintained under strong FLC
pressure for 5 days in the presence and absence of Dox. We
were first able to identify enriched and depleted isolates in
these conditions. The susceptibility profiles of these candidate
genes were further investigated in single strain assays to address
potential pool effects in the enrichment assay. We observed a
poor correlation between the pooled and single strain assays.
Among the possible explanations, the repeated subcultures as the
duration of the experiment (5 days) in the pooled experiment
compared to the single strain assay (1 day) might have created
several biases in the selection of FLC-tolerant strains. Even
considering these limitations, we came with a list of 12 putative
mediators of FLC tolerance by crossing these results of both
selection experiments. Only two of them, CRZ1 and GZF3,
could be linked to a significant increase of tolerance under
Dox induction above the clinical threshold (TI > 0.2). One
of these two genes was the calcineurin-regulated transcription
factor CRZ1, already identified to play a role in FLC tolerance
by Onyewu et al. (2004) and Karababa et al. (2006). To act as a
transcription factor, Crz1 needs to be translocated to the nucleus.
This is achieved by dephosphorylation via calcineurin, which is
known to act as a protein phosphatase (Karababa et al., 2006). In
this work, we showed that CRZ1 overexpression is triggering FLC
tolerance, which may be achieved by transcriptional activation
and thus a shift in the balance toward dephosphorylated
Crz1. The relationship between CRZ1 overexpression and Crz1
dephosphorylation has not been tested here but needs to be
addressed in future investigations. The other identified gene was
the putative GATA-type transcription factor GZF3, of which the
S. cerevisiae ortholog negatively regulates nitrogen catabolic gene
expression (Soussi-Boudekou et al., 1997). Little is known about
GZF3 function in C. albicans, but it was shown to be induced,
via Cap1, in oxidative stress conditions (Wang et al., 2006). Most
of the information on GZF3 come from Homann’s and Noble’s
phenotypic screens (Homann et al., 2009; Noble et al., 2010).
In their works, the homozygous gzf31/1 mutant resulted in
abnormal growth on Spider medium and decreased competitive
fitness in a mice systemic infection model. Homann et al. (2009)
also observed an increased susceptibility to heat, FLC, lithium
chloride, copper and rapamycin. However, no genetic clues could
explain these phenotypes so far. To our knowledge, it is the
first time here that GZF3 has been linked to an increase of
FLC tolerance when overexpressed in C. albicans. A third gene,
YCK2, was also identified. This gene encodes a plasma membrane
protein similar to the S. cerevisiae casein kinase I, which is
required for the membrane trafficking of Pdr5 (the ortholog of the
multidrug transporter CDR1 in S. cerevisiae) to the cell surfaces
(Decottignies et al., 1999). YCK2 overexpression significantly
increased FLC tolerance. However, it did not reach the threshold
of tolerance (TI < 0.2) defined for clinical isolates. This gene
remains, however, a good candidate for future investigations
on molecular mechanisms behind FLC tolerance. Interestingly,
YCK2 was showed recently as interfering with caspofungin
resistance (Caplan et al., 2020) and was shown earlier to be
involved in response to FLC (Jung et al., 2017). The single
strain assay also confirmed our pool enrichment protocol to be
a valuable approach for the identification of putative positive
mediators of FLC tolerance. Additional enrichment experiments
using extended OE collections might reveal novel insights into
the mechanisms behind this phenotype.
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To further characterize the possible interactions existing
between CRZ1 and GZF3 (since both could mediate FLC
tolerance), we observed that GZF3 significantly increased
tolerance when overexpressed, but only when at least a single
copy of CRZ1 was present. Taking the hypothesis that CRZ1
and GZF3 may be part of a same pathway, our results suggest
that Gzf3 acts upstream of Crz1. Further investigation of
Crz1 and Gzf3 target genes via RNA sequencing or chromatin
immunoprecipitation may reveal other proteins necessary to
increase FLC tolerance as well as highlighting the relation
between both TFs. Both CRZ1 and GZF3 were also shown
to play a role in FLC tolerance in clinical isolates. CRZ1
deletion significantly reduces FLC tolerance in the four tested
clinical strains (Figure 7) to levels below the tolerance threshold
(TI < 0.2) of clinical isolates. On the other hand, GZF3 deletion
was able to reduce tolerance levels but only when both alleles were
deleted in a specific isolate (DSY4588). Experiments aimed to re-
introduce CRZ1 and GZF3 in the background of deletion mutants
in clinical strains yielded different phenotypic complementation
results (Figure 7). For example, CRZ1 revertant isolates from
strains DSY2110 and DSY4454 did not revert to initial parent
wild type levels. The reversion of the full initial phenotype may
require that two CRZ1 copies are being re-introduced at their
genomic loci. The reversion of the initial phenotype may also
require the presence of CRZ1 alleles originating from the clinical
strains and not from SC5314. To confirm this hypothesis, future
experiments should introduce the CRZ1 alleles from the parental
clinical strains in their respective homozygote mutants. This
last hypothesis suggests that CRZ1 alleles from these clinical
strains could exhibit polymorphisms responsible for the gain
of FLC tolerance.
In a recent study published by the group of J. Berman,
some mechanistic insights into the basis of FLC tolerance were
given (Rosenberg et al., 2018). As suggested by our results, this
study highlighted that, using chemically induced phenotypes,
the calcineurin pathway was implicated in the development
of azole tolerance. The study of Rosenberg et al. (2018) used
mutants constructed in laboratory strains (for example crz1,
cnb1) and reduction of trailing growth on disk diffusion assays
to support their hypothesis. In addition, this study indicated that
the development of tolerance in clinical strains still susceptible
to FLC was attributed to distinct subpopulations (Rosenberg
et al., 2018). Among other interesting observations, Rosenberg
et al. (2018) observed that tolerant strains were more likely to be
isolated from FLC-treated patients than others, which suggested
that C. albicans may adapt to this drug. If azole treatment is
prolonged, tolerant isolates may persist and, thus, may cause
more severe damage to the host. However, the relationship
between occurrence of FLC tolerance and FLC efficacy is still
not clearly established in C. albicans. A study from Astvad et al.
(2018) undertaken with C. tropicalis isolates exhibiting different
tolerance profiles tested FLC efficacy in systemic mice infection
models. The data of this study established that high FLC tolerance
compromised the efficacy of FLC in the mice, thus suggesting a
clinical relevance of the tolerance phenomenon.
Transcriptomics is a powerful technology to address
gene function and to get insights in circuits activated
upon environmental perturbations. Chemical stress can
induce transcriptional changes reflecting both general (e.g.,
detoxification pathways) and specific responses of the organism
to alteration of one or more biological pathways that are
affected by treatment with the chemical (Hughes et al., 2000).
While drug exposed conditions can be helpful in revealing
biological meaningful data, the use of clinical strains with
specific phenotypes is also useful to identify the mechanisms
that control these phenotypes. In this work, we addressed the
transcript profiling of several isolates in the presence of FLC,
some of which exhibit FLC tolerance. The major difference in
these experiments as compared to similar published results using
C. albicans exposed to FLC was that the incubation conditions
were mimicking standard susceptibility assays performed
under EUCAST recommendations. In these conditions, we
showed here that FLC induced a response that included several
calcineurin-dependent genes. Such a response profile has not
yet been clearly demonstrated in published profiling studies
with FLC. Such an association strongly suggests that FLC
recruits the calcineurin pathway, which was already showed
to be critical for survival of C. albicans exposed to FLC
(Sanglard et al., 2003).
The clinical isolates used here in transcriptional analysis
were related to each other, which was expected to reduce
transcriptional noise that can arise from strains exhibiting
different genetic backgrounds. In these sequential isolates,
DSY4454 was the first recovered isolate from a patient suffering
from endocarditis. DSY4454 exhibited relative low TI as
compared to the other isolates (DSY4452 and DSY4588). The
patient had been treated for several years with FLC until
blood cultures were positive for DSY4452 and DSY4588 about
7 and 9 years after the isolation of DSY4454. It is likely
that the duration of FLC treatment along these years selected
for isolates with genome modifications favoring, among other
phenotypes, the development of azole tolerance. Comparative
genomics could lead to resolve the molecular basis of azole
tolerance in clinical isolates. This type of approach may be
rendered difficult due to the likely genome divergence that
evolved during the years of persistence of the strains in the
host. Our data revealed that several genes of the calcineurin
pathway were upregulated as compared to the initial isolate
(DSY4454). Currently the genetic basis for this modification
is unknown. In our transcript profiling data, CRZ1 was more
upregulated in the tolerant isolates as compared to wild type
isolates (by about 2-fold between DSY4452 and DSY4454
and between DSY4588 and DSY4454, Supplementary File
S7). As mentioned earlier in this work, CRZ1 overexpression
mediated by an artificial regulatable promoter is enough to
induce FLC tolerance in C. albicans. CRZ1 expression changes
could therefore be taken as a candidate marker for azole
tolerance. Interestingly, a recent study revealed that the copy
number of CRZ1 was correlated with the occurrence of FCL
tolerance in C. albicans isolates exposed to FLC. Assuming
that CRZ1 gene copy number may be correlated with increased
expression, this study corroborates with our observations (Todd
and Selmecki, 2020). How CRZ1 overexpression mediates
azole tolerance is still unknown. No detailed information
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currently exists on CRZ1 target genes that could ultimately
be responsible for azole tolerance. Identification of CRZ1
target genes that could mediate azole tolerance needs to be
systematically performed. In conclusion, even if the present
results converge to the involvement of the calcineurin pathway in
the development of azole tolerance, additional studies are needed
to resolve the molecular details behind this phenomenon.
DATA AVAILABILITY STATEMENT
The datasets presented in this study can be found in online
repositories. The names of the repository/repositories and
accession number(s) can be found in the article/Supplementary
Material.
AUTHOR CONTRIBUTIONS
ED wrote the manuscript and performed experiments. LB, ET,
MP, CP, and FM performed experiments. SZ, MC, ML and M-
EB provided material. Cd’E designed strategies. DS designed
strategies and wrote the manuscript. All authors contributed to
the article and approved the submitted version.
FUNDING
This work was supported by Swiss National Research Foundation
grants 31003A_146936 and 31003A_172958 to DS. The authors
thank Françoise Ischer and Danielle Brandalise for excellent
technical assistance and M. Arendrup for generous gift of
C. albicans isolates. The content of this manuscript has been
published as part of the thesis of ED (Delarze, 2019). SZ was
the recipient of post-doctoral fellowships from the European
Commission (FINSysB, PITN-GA-2008-214004), the Agence
Nationale de la Recherche (KANJI, ANR-08-MIE-033-01) and
the French Government’s Investissement d’Avenir program
(Institut de Recherche Technologique BIOASTER, ANR-10-
AIRT-03). Cd’E is supported by the French Government’s
Investissement d’Avenir program (Laboratoire d’Excellence
Integrative Biology of Emerging Infectious Diseases, ANR-10-
LABX-62-IBEID).
SUPPLEMENTARY MATERIAL




Amorim-Vaz, S., Tran Vdu, T., Pradervand, S., Pagni, M., Coste, A. T., and
Sanglard, D. (2015). RNA enrichment method for quantitative transcriptional
analysis of pathogens in vivo applied to the fungus Candida albicans. mBio
6:e00942-15. doi: 10.1128/mBio.00942-15
Astvad, K. M. T., Sanglard, D., Delarze, E., Hare, R. K., and Arendrup, M. C. (2018).
Implications of the EUCAST trailing phenomenon in candida tropicalis for the
in vivo susceptibility in invertebrate and murine models. Antimicrob. Agents
Chemother. 62:e01624-18. doi: 10.1128/AAC.01624-18
Berman, J., and Krysan, D. J. (2020). Drug resistance and tolerance in fungi. Nat.
Rev. Microbiol. 18, 319–331. doi: 10.1038/s41579-019-0322-2
Calabrese, D., Bille, J., and Sanglard, D. (2000). A novel multidrug efflux
transporter gene of the major facilitator superfamily from Candida albicans
(FLU1) conferring resistance to fluconazole. Microbiology 146(Pt 11), 2743–
2754. doi: 10.1099/00221287-146-11-2743
Caplan, T., Lorente-Macias, A., Stogios, P. J., Evdokimova, E., Hyde, S., Wellington,
M. A., et al. (2020). Overcoming fungal echinocandin resistance through
inhibition of the non-essential stress kinase Yck2. Cell Chem. Biol. 27, 269.e5–
282.e5. doi: 10.1016/j.chembiol.2019.12.008
Chauvel, M., Nesseir, A., Cabral, V., Znaidi, S., Goyard, S., Bachellier-Bassi, S.,
et al. (2012). A versatile overexpression strategy in the pathogenic yeast candida
albicans: identification of regulators of morphogenesis and fitness. PLoS One
7:e45912. doi: 10.1371/journal.pone.0045912
Clinical, and Laboratory Standards Institute [CLSI], (2008). Reference Method for
Broth Dilution Antifungal Susceptibility Testing of Yeasts; Approved Standard - -
Document M27-A3, 3rd Edn, ed. CLSI, (Wayne, PA: CLSI).
Cowen, L. E. (2008). The evolution of fungal drug resistance: modulating the
trajectory from genotype to phenotype. Nat. Rev. Microbiol. 6, 187–198.
Cowen, L. E. (2013). The fungal Achilles’ heel: targeting Hsp90 to cripple fungal
pathogens. Curr. Opin. Microbiol. 16, 377–384. doi: 10.1016/j.mib.2013.03.005
Decottignies, A., Owsianik, G., and Ghislain, M. (1999). Casein Kinase
I-dependent phosphorylation and stability of the yeast multidrug
transporter Pdr5p. J. Biol. Chem. 274, 37139–37146. doi: 10.1074/jbc.274.52.
37139
Delarze, E. (2019). Identification and Characterization of Mediators of Fluconazole
Tolerance in Candida albicans. Thesis. Lausanne: University of Lausanne.
Delarze, E., and Sanglard, D. (2015). Defining the frontiers between antifungal
resistance, tolerance and the concept of persistence. Drug Resist. Updat. 23,
12–19. doi: 10.1016/j.drup.2015.10.001
Dunkel, N., Blaß, J., Rogers, P. D., and Morschhäuser, J. (2008). Mutations in
the multi-drug resistance regulator MRR1, followed by loss of heterozygosity,
are the main cause of MDR1 overexpression in fluconazole-resistant Candida
albicans strains. Mol. Microbiol. 69, 827–840. doi: 10.1111/j.1365-2958.2008.
06309.x
European Committee on Antimicrobial Susceptibility Testing, (2017). EUCAST
DEFINITIVE DOCUMENT E.DEF 7.3.1 - Method for the Determination of Broth
Dilution Minimum Inhibitory Concentrations of Antifungal Agents for Yeasts.
Sweden: European Committee on Antimicrobial Susceptibility Testing.
Fiori, A., and Van Dijck, P. (2012). Potent synergistic effect of doxycycline with
fluconazole against Candida albicans is mediated by interference with iron
homeostasis. Antimicrob. Agents Chemother. 56, 3785–3796. doi: 10.1128/AAC.
06017-11
Gao, J., Wang, H., Li, Z., Wong, A. H.-H. H., Wang, Y. Y.-Z. Z. Y., Guo, Y.,
et al. (2018). Candida albicans gains azole resistance by altering sphingolipid
composition. Nat. Commun. 9, 1–14. doi: 10.1038/s41467-018-06944-1
Garnaud, C., García-Oliver, E., Wang, Y., Maubon, D., Bailly, S., Despinasse,
Q., et al. (2018). The rim pathway mediates antifungal tolerance in Candida
albicans through newly identified Rim101 transcriptional targets, including
Hsp90 and Ipt1. Antimicrob. Agents Chemother. 62:e01785-17. doi: 10.1128/
AAC.01785-17
Gerstein, A. C., Rosenberg, A., Hecht, I., Berman, J., and DiskimageR. (2016).
Quantification of resistance and tolerance to antimicrobial drugs using disk
diffusion assays. Microbiology 162, 1059–1068. doi: 10.1099/mic.0.000295
Gow, N. A. R., Bougnoux, M.-E., Odds, F. C., D’Enfert, C., Magnier, A., Maiden,
M. C. J., et al. (2003). Collaborative consensus for optimized multilocus
sequence typing of Candida albicans. J. Clin. Microbiol. 41, 5265–5266. doi:
10.1128/jcm.41.11.5265-5266.2003
Homann, O. R., Dea, J., Noble, S. M., and Johnson, A. D. (2009). A phenotypic
profile of the Candida albicans regulatory network. PLoS Genet. 5:e1000783.
doi: 10.1371/journal.pgen.1000783
Hughes, T. R., Marton, M. J., Jones, A. R., Roberts, C. J., Stoughton, R., Armour,
C. D., et al. (2000). Functional discovery via a compendium of expression
profiles. Cell 102, 109–126. doi: 10.1016/S0092-8674(00)00015-5
Frontiers in Microbiology | www.frontiersin.org 18 November 2020 | Volume 11 | Article 591140
fmicb-11-591140 November 6, 2020 Time: 11:49 # 19
Delarze et al. Candida albicans Azole Tolerance
Jung, S. I., Rodriguez, N., Irrizary, J., Liboro, K., Bogarin, T., Macias, M., et al.
(2017). Yeast casein kinase 2 governs morphology, biofilm formation, cell wall
integrity, and host cell damage of Candida albicans. PLoS One 12:e0187721.
doi: 10.1371/journal.pone.0187721
Karababa, M., Valentino, E., Pardini, G., Coste, A. T., Bille, J., and Sanglard, D.
(2006). CRZ1, a target of the calcineurin pathway in Candida albicans. Mol.
Microbiol. 59, 1429–1451. doi: 10.1111/j.1365-2958.2005.05037.x
Keller, P., Müller, C., Engelhardt, I., Hiller, E., Lemuth, K., Eickhoff, H., et al.
(2015). An antifungal benzimidazole derivative inhibits ergosterol biosynthesis
and reveals novel sterols. Antimicrob. Agents Chemother. 59, 6296–6307. doi:
10.1128/AAC.00640-15
Luna-Tapia, A., Kerns, M. E., Eberle, K. E., Jursic, B. S., and Palmer, G. E.
(2015). Trafficking through the late endosome significantly impacts Candida
albicans tolerance of the azole antifungals. Antimicrob. Agents Chemother. 59,
2410–2420. doi: 10.1128/AAC.04239-14
Marr, K. A., Rustad, T. R., Rex, J. H., and White, C. (1999). The trailing end point
phenotype in antifungal susceptibility testing is pH dependent. Antimicrob.
Agents Chemother. 43, 1383–1386. doi: 10.1128/AAC.43.6.1383
Matuszewski, S., Hildebrandt, M. E., Ghenu, A. H., Jensen, J. D., and Bank,
C. (2016). A statistical guide to the design of deep mutational scanning
experiments. Genetics 204, 77–87. doi: 10.1534/genetics.116.190462
Morschhäuser, J. (2016). The development of fluconazole resistance in Candida
albicans – an example of microevolution of a fungal pathogen. J. Microbiol. 54,
192–201. doi: 10.1007/s12275-016-5628-4
Noble, S. M., French, S., Kohn, L. A., Chen, V., and Johnson, A. D. (2010).
Systematic screens of a Candida albicans homozygous deletion library decouple
morphogenetic switching and pathogenicity. Nat. Genet. 42, 590–598. doi: 10.
1038/ng.605
Onyewu, C., Wormley, F. L., Perfect, J. R., and Heitman, J. (2004). The calcineurin
target, Crz1, functions in azole tolerance but is not required for virulence of
Candida albicans. Infect. Immun. 72, 7330–7333. doi: 10.1128/IAI.72.12.7330-
7333.2004
Pappas, P. G., Lionakis, M. S., Arendrup, M. C., Ostrosky-Zeichner, L., and
Kullberg, B. J. (2018). Invasive candidiasis. Nat. Rev. Dis. Prim. 4, 1–20. doi:
10.1038/nrdp.2018.26
Pfaller, M. A., and Diekema, D. J. (2010). Epidemiology of invasive mycoses in
North America. Crit. Rev. Mcrobiol. 36, 1–53. doi: 10.3109/10408410903241444
Reuss, O., Vik, A., Kolter, R., and Morschhäuser, J. (2004). The SAT1 flipper, an
optimized tool for gene disruption in Candida albicans. Gene 341, 119–127.
doi: 10.1016/j.gene.2004.06.021
Rosenberg, A., Ene, I. V., Bibi, M., Zakin, S., Segal, E. S., Ziv, N., et al. (2018).
Antifungal tolerance is a subpopulation effect distinct from resistance and is
associated with persistent candidemia. Nat. Commun. 9:2470. doi: 10.1038/
s41467-018-04926-x
Sanglard, D. (2003). Resistance and tolerance mechanisms to antifungal drugs in
fungal pathogens. Mycologist 17, 74–78. doi: 10.1017/S0269915X03002076
Sanglard, D., Ischer, F., Marchetti, O., Entenza, J., and Bille, J. (2003). Calcineurin
A of Candida albicans: involvement in antifungal tolerance, cell morphogenesis
and virulence. Mol. Microbiol. 48, 959–976. doi: 10.1046/j.1365-2958.2003.
03495.x
Sanglard, D., Ischer, F., Monod, M., and Bille, J. (1996). Susceptibilities of Candida
albicans multidrug transporter mutants to various antifungal agents and other
metabolic inhibitors. Antimicrob. Agents Chemother. 40, 2300–2305. doi: 10.
1128/AAC.40.10.2300
Soussi-Boudekou, S. S., Vissers, S., Urrestarazu, A., Jauniaux, J.-C. C., André,
B., and Andre, B. (1997). Gzf3P, a fourth GATA factor involved in nitrogen-
regulated transcription in Saccharomyces cerevisiae. Mol. Microbiol. 23, 1157–
1168. doi: 10.1046/j.1365-2958.1997.3021665.x
Todd, R. T., and Selmecki, A. (2020). Expandable and reversible copy number
amplification drives rapid adaptation to antifungal drugs. eLife 9:e58349. doi:
10.7554/eLife.58349
Vasicek, E. M., Berkow, E. L., Bruno, V. M., Mitchell, A. P., Wiederhold, N. P.,
Barker, K. S., et al. (2014). Disruption of the transcriptional regulator Cas5
results in enhanced killing of Candida albicans by fluconazole. Antimicrob.
Agents Chemother. 58, 6807–6818. doi: 10.1128/AAC.00064-14
Wang, Y., Cao, Y.-Y., Jia, X.-M., Cao, Y.-B., Gao, P.-H., Fu, X.-P., et al. (2006).
Cap1p is involved in multiple pathways of oxidative stress response in Candida
albicans. Free Radic. Biol. Med. 40, 1201–1209. doi: 10.1016/j.freeradbiomed.
2005.11.019
Wellington, M., and Rustchenko, E. (2005). 5-Fluoro-orotic acid induces
chromosome alterations in Candida albicans. Yeast 22, 57–70. doi: 10.1002/yea.
1191
Whaley, S. G., Tsao, S., Weber, S., Zhang, Q., Barker, K. S., Raymond, M.,
et al. (2016). The RTA3 gene, encoding a putative lipid translocase, influences
the susceptibility of Candida albicans to fluconazole. Antimicrob. Agents
Chemother. 60, 6060–6066. doi: 10.1128/AAC.00732-16
Znaidi, S., van Wijlick, L., Hernández-Cervantes, A., Sertour, N., Desseyn, J. L.,
Vincent, F., et al. (2018). Systematic gene overexpression in Candida albicans
identifies a regulator of early adaptation to the mammalian gut. Cell. Microbiol.
20, 1–21. doi: 10.1111/cmi.12890
Conflict of Interest: ED is employed by Resistcell AG. CP is employed by Abionic
SA. FM is employed by Philip Morris Product SA.
The remaining authors declare that the research was conducted in the absence of
any commercial or financial relationships that could be construed as a potential
conflict of interest.
Copyright © 2020 Delarze, Brandt, Trachsel, Patxot, Pralong, Maranzano, Chauvel,
Legrand, Znaidi, Bougnoux, d’Enfert and Sanglard. This is an open-access article
distributed under the terms of the Creative Commons Attribution License (CC BY).
The use, distribution or reproduction in other forums is permitted, provided the
original author(s) and the copyright owner(s) are credited and that the original
publication in this journal is cited, in accordance with accepted academic practice.
No use, distribution or reproduction is permitted which does not comply with
these terms.
Frontiers in Microbiology | www.frontiersin.org 19 November 2020 | Volume 11 | Article 591140
